Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Assets Average (2022 - 2025)

Atara Biotherapeutics' Assets Average history spans 4 years, with the latest figure at $25.2 million for Q4 2025.

  • For Q4 2025, Assets Average fell 79.98% year-over-year to $25.2 million; the TTM value through Dec 2025 reached $25.2 million, down 79.98%, while the annual FY2025 figure was $64.7 million, 52.9% down from the prior year.
  • Assets Average reached $25.2 million in Q4 2025 per ATRA's latest filing, down from $33.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $416.7 million in Q2 2022 to a low of $25.2 million in Q4 2025.
  • Average Assets Average over 4 years is $197.1 million, with a median of $165.4 million recorded in 2024.
  • Peak YoY movement for Assets Average: decreased 28.93% in 2024, then plummeted 79.98% in 2025.
  • A 4-year view of Assets Average shows it stood at $372.4 million in 2022, then tumbled by 52.43% to $177.1 million in 2023, then fell by 28.93% to $125.9 million in 2024, then tumbled by 79.98% to $25.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Assets Average are $25.2 million (Q4 2025), $33.5 million (Q3 2025), and $49.5 million (Q2 2025).